Cancel
Nektar Therapeutics
Nektar Therapeutics Employees
7 people indexed:
-
xp9l93.2ulfs@vz4j67.vy3 Sign up to see email
-
b37zb9yz.70v6954@30b5bh.3l9 Sign up to see email
-
Jonathan Zalevsky, Ph.D.
Chief Research & Development Officer
226bx54d.7u7g8i52@q49i7b.f2q Sign up to see emailqpg2q125.03388ii1@q1x690.630 Sign up to see email -
p8j2.dvyfhb@91jpdu.dy3 Sign up to see email
-
j670.24z24888d6u@sj1073.p57 Sign up to see email
-
Robert Bacci
Senior Vice President, HR and Facilities Operations
su738d.xhj20@zqlj52.ssp Sign up to see email3xd39g.g2ylu@4p0sjv.6pd Sign up to see email -
f882vx.7f7lb3u0@v96y1j.x22 Sign up to see email
Nektar Therapeutics Company Information
Nektar Therapeutics specializes in the discovery and development of innovative therapies that selectively modulate the immune system. The company leverages its deep understanding of immunology combined with expertise in polymer chemistry to develop unique, highly-selective medicines. Nektar’s portfolio includes life-changing medicines that are globally commercialized by various pharmaceutical partners. The company is actively engaged in developing therapies targeting cytokine pathways and other mechanisms relevant to autoimmune disorders, chronic inflammatory conditions, and cancer. Nektar operates a research and development center along with its corporate headquarters in San Francisco, California, and maintains additional office and facilities in Huntsville, Alabama. Recently, the company announced a $30 million private placement financing with TCGX and initiated a Phase 2b clinical study evaluating Rezpegaldesleukin in patients with severe to very severe Alopecia Areata.
Report inaccurate information
Report inaccurate information
